{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:04:10Z","timestamp":1792195450190,"version":"4.4.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of this meta-analysis was to evaluate the effects of targeted treatments for transthyretin amyloid cardiomyopathy (ATTR-CM) on clinical outcomes by integrating clinical trial and real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A systematic literature search of PubMed was conducted up to 30 June 2025. A total of 714 relevant records were identified; out of 51 potentially eligible studies, 10 randomized placebo-controlled and non-randomized control comparison studies were selected, with available outcome data on all-cause mortality and cardiovascular hospitalizations. The estimates were extrapolated to real-world outcome data of untreated ATTR-CM patients to estimate absolute risk reduction (ARR) and number needed to treat (NNT). Ten studies comprising 5203 patients were included. ATTR-targeted treatments reduced mortality by 39% [risk ratio (RR) 0.61, 95% confidence interval (CI): 0.52 to 0.70, I2 = 35%, P = 0.13]. A sensitivity subgroup analysis for RCT only confirmed a 28% reduction in all-cause mortality (RR 0.72, 95% CI: 0.60 to 0.86, I2 = 0%, P = 0.56). The random effects model for cardiovascular hospitalizations demonstrated a 31% reduction in the ATTR-targeted treatment group compared with control (RR: 0.69, 95% CI: 0.53 to 0.89, I2 = 68%, P = 0.01). By applying these estimates to published large-scale epidemiological data on the natural disease course from 18238 untreated patients, the estimated NNT of ATTR-CM therapeutics to prevent one death is an NNT of 10 at 2 years and an NNT of 5 at 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Targeted treatments for ATTR-CM significantly reduce mortality and cardiovascular hospitalizations. When extrapolated to population-level data, these treatments show clinical benefits, emphasizing the importance of early diagnosis and therapeutic intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.70011","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:31:05Z","timestamp":1764322265000},"page":"4475-4485","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Effectiveness of Targeted Therapies in ATTR Cardiomyopathy: A Meta-Analysis Integrating Population-Based Data"],"prefix":"10.1093","volume":"12","author":[{"given":"Alexios S.","family":"Antonopoulos","sequence":"first","affiliation":[{"name":"Cardiogenetics Unit, First Cardiology Department, Hippokration Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Tsampras","sequence":"additional","affiliation":[{"name":"Cardiogenetics Unit, First Cardiology Department, Hippokration Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Terentes-Printzios","sequence":"additional","affiliation":[{"name":"Cardiogenetics Unit, First Cardiology Department, Hippokration Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Lazaros","sequence":"additional","affiliation":[{"name":"Cardiogenetics Unit, First Cardiology Department, Hippokration Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"Cardiogenetics Unit, First Cardiology Department, Hippokration Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Vlachopoulos","sequence":"additional","affiliation":[{"name":"Cardiogenetics Unit, First Cardiology Department, Hippokration Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2026021804135262000_ehf270011-bib-0001","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/13506129.2022.2159369","article-title":"Cardiac amyloidosis remains significantly underdiagnosed in patients undergoing TAVR: analysis of national inpatient sample","volume":"30","author":"Terentes-Printzios","year":"2023","journal-title":"Amyloid"},{"key":"2026021804135262000_ehf270011-bib-0002","doi-asserted-by":"publisher","first-page":"E128","DOI":"10.1093\/eurheartj\/suab107","article-title":"Transthyretin amyloidosis in aortic stenosis: clinical and therapeutic implications","volume":"23","author":"Fabbri","year":"2021","journal-title":"Eur Heart J Suppl"},{"key":"2026021804135262000_ehf270011-bib-0003","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021804135262000_ehf270011-bib-0004","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","article-title":"Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness","volume":"27","author":"Nativi-Nicolau","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2026021804135262000_ehf270011-bib-0005","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.hjc.2023.05.004","article-title":"The patient pathway in ATTR-CM in Greece and how to improve it: a multidisciplinary perspective","volume":"73","author":"Apostolou","year":"2023","journal-title":"Hellenic J Cardiol"},{"key":"2026021804135262000_ehf270011-bib-0006","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026021804135262000_ehf270011-bib-0007","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","article-title":"Characteristics and natural history of early-stage cardiac transthyretin amyloidosis","volume":"43","author":"Law","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021804135262000_ehf270011-bib-0008","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1002\/ehf2.12989","article-title":"Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage","volume":"7","author":"Law","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026021804135262000_ehf270011-bib-0009","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"2026021804135262000_ehf270011-bib-0010","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14797\/mdcvj.1066","article-title":"ATTR epidemiology, genetics, and prognostic factors","volume":"18","author":"Obi","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"2026021804135262000_ehf270011-bib-0011","doi-asserted-by":"publisher","first-page":"985","DOI":"10.5603\/CJ.a2020.0104","article-title":"Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis","volume":"29","author":"Gawor","year":"2022","journal-title":"Cardiol J"},{"key":"2026021804135262000_ehf270011-bib-0012","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamacardio.2024.2190","article-title":"Prevalence, cardiac phenotype, and outcomes of transthyretin variants in the UK biobank population","volume":"9","author":"Aung","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026021804135262000_ehf270011-bib-0013","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804135262000_ehf270011-bib-0014","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021804135262000_ehf270011-bib-0015","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021804135262000_ehf270011-bib-0016","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"2026021804135262000_ehf270011-bib-0017","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s40120-023-00522-4","article-title":"Impact of Vutrisiran on quality of life and physical function in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"12","author":"Obici","year":"2023","journal-title":"Neurol Ther"},{"key":"2026021804135262000_ehf270011-bib-0018","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804135262000_ehf270011-bib-0019","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026021804135262000_ehf270011-bib-0020","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026021804135262000_ehf270011-bib-0021","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12872-025-04653-4","article-title":"The efficacy and safety of specific therapies for cardiac transthyretin-mediated amyloidosis: a systematic review and meta-analysis of randomized trials","volume":"25","author":"Prata","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"2026021804135262000_ehf270011-bib-0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102172","article-title":"Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis","volume":"63","author":"Wang","year":"2023","journal-title":"EClinMed"},{"key":"2026021804135262000_ehf270011-bib-0023","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"2026021804135262000_ehf270011-bib-0024","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/eurheartj\/ehae923","article-title":"Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study","volume":"46","author":"Debonnaire","year":"2025","journal-title":"Eur Heart J"},{"key":"2026021804135262000_ehf270011-bib-0025","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf362","article-title":"Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis","author":"Nitsche","year":"2025","journal-title":"Eur Heart J"},{"key":"2026021804135262000_ehf270011-bib-0026","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","article-title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the transthyretin amyloidosis outcomes survey (THAOS)","volume":"31","author":"Garcia-Pavia","year":"2025","journal-title":"J Card Fail"},{"key":"2026021804135262000_ehf270011-bib-0027","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","article-title":"Early experience of Tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort","volume":"86","author":"Ochi","year":"2022","journal-title":"Circ J: Official J Japanese Circ Soc"},{"key":"2026021804135262000_ehf270011-bib-0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101667","article-title":"Real-world efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure","volume":"48","author":"Ghoneem","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2026021804135262000_ehf270011-bib-0029","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026021804135262000_ehf270011-bib-0030","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026021804135262000_ehf270011-bib-0031","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","article-title":"Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy","volume":"30","author":"Rettl","year":"2023","journal-title":"Amyloid"},{"key":"2026021804135262000_ehf270011-bib-0032","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804135262000_ehf270011-bib-0033","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026021804135262000_ehf270011-bib-0034","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1002\/ehf2.14815","article-title":"Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy","volume":"11","author":"Dobner","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021804135262000_ehf270011-bib-0035","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1097\/MJT.0000000000001296","article-title":"Targeted therapeutics for transthyretin amyloid cardiomyopathy","volume":"30","author":"Campbell","year":"2023","journal-title":"Am J Ther"},{"key":"2026021804135262000_ehf270011-bib-0036","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1002\/ehf2.12986","article-title":"Heart failure from ATTRwt amyloid cardiomyopathy is associated with poor prognosis","volume":"7","author":"Kocher","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026021804135262000_ehf270011-bib-0037","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamacardio.2020.1738","article-title":"Initial experience prescribing commercial tafamidis, the most expensive cardiac medication in history","volume":"5","author":"Masri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026021804135262000_ehf270011-bib-0038","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1053\/j.jvca.2024.02.035","article-title":"It's time for effective and affordable therapies for cardiac amyloidosis: lessons from patisiran","volume":"38","author":"Williams","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2026021804135262000_ehf270011-bib-0039","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40256-022-00526-9","article-title":"Annual cardiovascular-related hospitalization days avoided with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"22","author":"Rozenbaum","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026021804135262000_ehf270011-bib-0040","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jchf.2020.08.004","article-title":"Estimating the lifetime benefits of treatments for heart failure","volume":"8","author":"Ferreira","year":"2020","journal-title":"JACC: Heart Fail"},{"key":"2026021804135262000_ehf270011-bib-0041","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jamacardio.2018.3957","article-title":"Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial","volume":"3","author":"Srivastava","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026021804135262000_ehf270011-bib-0042","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ehf2.14213","article-title":"Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes","volume":"10","author":"Wolff","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026021804135262000_ehf270011-bib-0043","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"2026021804135262000_ehf270011-bib-0044","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"2026021804135262000_ehf270011-bib-0045","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1060028019888489","article-title":"Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy","volume":"54","author":"Park","year":"2020","journal-title":"Ann Pharmacother"},{"key":"2026021804135262000_ehf270011-bib-0046","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1358\/dot.2019.55.12.3078389","article-title":"Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy","volume":"55","author":"Paton","year":"2019","journal-title":"Drugs Today (Barc)"},{"key":"2026021804135262000_ehf270011-bib-0047","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041129","article-title":"Transthyretin stabilizers and seeding inhibitors as therapies for amyloid transthyretin cardiomyopathy","volume":"15","author":"Morfino","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026021804135262000_ehf270011-bib-0048","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40291-019-00434-w","article-title":"Leading RNA interference therapeutics part 1: silencing hereditary transthyretin amyloidosis, with a focus on patisiran","volume":"24","author":"Titze-de-Almeida","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"2026021804135262000_ehf270011-bib-0049","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cardfail.2024.10.019","article-title":"A comparison of single versus dual treatment with stabilizers and silencers in transthyretin amyloid cardiomyopathy","volume":"31","author":"Vaishnav","year":"2025","journal-title":"J Card Fail"},{"key":"2026021804135262000_ehf270011-bib-0050","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"2026021804135262000_ehf270011-bib-0051","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026021804135262000_ehf270011-bib-0052","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jchf.2023.08.032","article-title":"Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study","volume":"12","author":"Garcia-Pavia","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026021804135262000_ehf270011-bib-0053","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener Dis Manag"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4475\/66968240\/eschf_12_6_4475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4475\/66968240\/eschf_12_6_4475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:13:57Z","timestamp":1771406037000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/6\/4475\/8488149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11,28]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.70011","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"2025-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}